Rhythm Pharmaceuticals, Inc.(RYTM)

Description: Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

---

Keywords: Biopharmaceutical Organ Systems Obesity Peptides Metabolic Disorders Peptide Hormones Genetic Disorder Monogenic Melanocortin Neuropeptides Bardet Biedl Syndrome Ciliopathy Homeostasis Leptin Pomc Epigenetic Disorders Proopiomelanocortin Setmelanotide

---

Home Page: www.rhythmtx.com

RYTM Technical Analysis

222 Berkeley Street
Boston, MA 02116
United States
Phone: 857 264 4280

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)